GRI Bio, Inc. (GRI)
GRI moved a median of -0.97% 30 minutes after news, and -3.12% by the close. How GRI actually reacts to news — the realized, point-in-time move the market made, measured across 249 labeled events over the last three years with zero look-ahead.
GRI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 39% | 246 |
| 30-min | -0.97% | 36% | 249 |
| 60-min | -1.53% | 37% | 249 |
| to close | -3.12% | 28% | 249 |
| Middle 50% of GRI reactions | -4.44% to +1.02% |
|---|---|
| Median reaction (30-min) | -0.97% |
| Measured reactions | 249 |
Half of all GRI Bio, Inc. news events land between -4.44% and +1.02% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when GRI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GRI's baseline. Nothing else.
Recent GRI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form ARS GRI Bio, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | — | -5.66% | |
| Form DEF 14A GRI Bio, Inc. For: Nov 04 | SEC filing · Form DEF | SEC EDGAR | — | -5.66% | |
| GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit | Press release | GlobeNewswire | -3.34% | +1.45% | |
| Form 8-K GRI Bio, Inc. For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | -1.92% | -23.37% | |
| GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars | Press release | GlobeNewswire | -1.92% | -23.37% | |
| GRI Bio Featured in "Why Now" On-Demand Video Webcast | Press release | GlobeNewswire | -3.65% | +7.81% | |
| GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026 | Press release | GlobeNewswire | -1.56% | -0.56% | |
| Form 10-Q GRI Bio, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.55% | -8.24% | |
| Form 8-K GRI Bio, Inc. For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -1.05% | -1.58% | |
| GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis | Press release | GlobeNewswire | -2.37% | -10.90% | |
| GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase | Press release | GlobeNewswire | +0.99% | +6.47% | |
| Form 8-K GRI Bio, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -0.44% | -3.59% | |
| GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline | Press release | GlobeNewswire | -0.44% | -3.59% | |
| Form 10-Q GRI Bio, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.44% | -3.59% | |
| GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions | Press release | GlobeNewswire | -2.22% | -3.23% | |
| GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment | Press release | GlobeNewswire | +0.33% | +2.21% | |
| GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial | Press release | GlobeNewswire | -1.92% | -16.09% | |
| Form 8-K GRI Bio, Inc. For: Feb 04 | SEC filing · Form 8-K | SEC EDGAR | -6.80% | +5.60% | |
| GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights | Press release | GlobeNewswire | -6.80% | +5.60% | |
| Form EFFECT GRI Bio, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.06% | -11.18% | |
| Form 10-K GRI Bio, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.37% | -3.26% | |
| Form 8-K GRI Bio, Inc. For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | +2.37% | -3.26% | |
| Form S-3 GRI Bio, Inc. | SEC filing · Form S-3 | SEC EDGAR | +2.37% | -3.26% | |
| Form S-8 GRI Bio, Inc. | SEC filing · Form S-8 | SEC EDGAR | +2.37% | -3.26% | |
| Form 8-K GRI Bio, Inc. For: Jan 28 | SEC filing · Form 8-K | SEC EDGAR | -7.73% | -33.82% | |
| GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF | Press release | GlobeNewswire | -7.73% | -33.82% | |
| GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures | Press release | GlobeNewswire | -1.62% | -1.42% | |
| Form 8-K GRI Bio, Inc. For: Jan 21 | SEC filing · Form 8-K | SEC EDGAR | -6.28% | -1.90% | |
| GRI Bio Announces Reverse Stock Split | Press release | GlobeNewswire | -6.28% | -1.90% | |
| Form 8-K GRI Bio, Inc. For: Jan 15 | SEC filing · Form 8-K | SEC EDGAR | -6.35% | -11.71% | |
| Form 8-K GRI Bio, Inc. For: Jan 15 | SEC filing · Form 8-K | SEC EDGAR | +0.97% | +4.06% | |
| Form 8-K GRI Bio, Inc. For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | -1.81% | -13.46% | |
| Form 8-K GRI Bio, Inc. For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +3.14% | -7.19% | |
| GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621 | Press release | GlobeNewswire | +3.14% | -7.19% | |
| Form DEF 14A GRI Bio, Inc. For: Jan 15 | SEC filing · Form DEF | SEC EDGAR | +0.66% | -12.09% | |
| Form PRE 14A GRI Bio, Inc. For: Dec 19 | SEC filing · Form PRE | SEC EDGAR | -1.22% | -7.10% | |
| Form 8-K GRI Bio, Inc. For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | +0.13% | -3.12% | |
| Form 8-K GRI Bio, Inc. For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | -3.85% | -8.65% | |
| Form EFFECT GRI Bio, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.13% | -3.12% | |
| GRI Bio Announces Closing of $8.0 Million Public Offering | Press release | GlobeNewswire | -3.85% | -8.65% | |
| GRI Bio Announces Pricing of $8,000,000 Million Public Offering | Press release | GlobeNewswire | +19.74% | -5.89% | |
| Form 8-K GRI Bio, Inc. For: Dec 10 | SEC filing · Form 8-K | SEC EDGAR | +19.74% | -5.89% | |
| Form S-1/A GRI Bio, Inc. | SEC filing · Form S-1 | SEC EDGAR | -5.93% | -10.37% | |
| GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) | Press release | GlobeNewswire | +19.74% | -5.89% | |
| Form 8-K GRI Bio, Inc. For: Dec 08 | SEC filing · Form 8-K | SEC EDGAR | -30.85% | -28.19% | |
| Form S-1 GRI Bio, Inc. | SEC filing · Form S-1 | SEC EDGAR | -30.85% | -28.19% | |
| Form 8-K GRI Bio, Inc. For: Nov 26 | SEC filing · Form 8-K | SEC EDGAR | -5.34% | +1.04% | |
| Form 10-Q GRI Bio, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.88% | +5.63% | |
| GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) | Press release | GlobeNewswire | +15.42% | -4.21% | |
| GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference | Press release | GlobeNewswire | -0.72% | +5.04% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GRI section they belong to.
Where else GRI is measured.
GRI earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is GRI Bio, Inc.'s median reaction calculated?
Every labeled GRI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 249 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 36% of GRI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GRI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.